Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. - Wikidata - awgldk - TriplyDB

Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.

Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.

http://www.wikidata.org/entity/Q44136140

about

Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease Hypoglycemic agents and potential anti-inflammatory activity Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.Additive effects of atorvastatin combined with sitagliptin on rats with myocardial infarction: a pilot study DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.Acute myocardial infarction associated to DPP-4 inhibitors Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease.Treating coronary disease and the impact of endothelial dysfunction.Predictive value of endothelial function by noninvasive peripheral arterial tonometry for coronary artery disease Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial.DPP-4 Inhibitor Reduces Central Blood Pressure in a Diabetic and Hypertensive Patient: A Case Report.Lack of correlation between the optimal glycaemic control and coronary micro vascular dysfunction in patients with diabetes mellitus: a cross sectional study A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients.Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up.Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS).The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus.Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study.Sitagliptin attenuates inﬂammatory responses in lipopolysaccharide-stimulated cardiomyocytes via nuclear factor-κB pathway inhibition Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study.Peripheral endothelial function and cardiovascular events in high-risk patients Effects of sitagliptin on coronary atherosclerosis in patients with type 2 diabetes-A serial integrated backscatter-intravascular ultrasound study Clinical Implication of Plasma Hydrogen Sulfide Levels in Japanese Patients with Type 2 Diabetes.Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluat Association between obstructive sleep apnea severity and endothelial dysfunction in patients with type 2 diabetes Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.Potential anti-atherosclerotic effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus.Is there a role for the incretin system in blood pressure regulation?Antiatherothrombotic effects of dipeptidyl peptidase inhibitors.Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies.

P2860

Q26741067-BEF8B5EA-6D34-42EE-9A2F-345ECE35450C Q26750414-A5C816BE-5774-4293-B1D3-6A04DC23D072 Q26778329-224B383F-B17A-4874-81BD-81B4EBE752E2 Q26784211-FCADCECB-7B6B-4074-9436-64AE2FE960A7 Q26795473-81BD0A39-BB45-4DCB-B2CC-980139DDFF67 Q27021870-FAF0231C-CFC9-4E1D-844D-A2A83AD349F4 Q33556240-BD157202-15EB-40C0-9E38-2BAF0B3DB8DF Q33904475-63FB064D-9F42-4548-87EA-87D07070A99B Q34109066-487647D3-7DA2-47A4-A617-49872B62C1C8 Q34272594-7FDBD1B2-4BAD-45C8-99A4-BC9F51B5815E Q34783302-0AFBF67A-E3E9-4DEB-B31F-D07E2622ED1B Q35196366-5F1F30B7-875B-4033-B26A-053B08E8EFD6 Q35269594-FD2C23DA-CDF4-4BDC-B23A-2EF3EFFE8B7D Q35666901-6B763B3D-DAF4-43C2-B268-85833DD5B189 Q35858226-5A4F7ECE-B664-4B88-8DDB-89DA9516C81A Q35951214-53013C6E-BDCB-40CA-A765-D6CB18FF4258 Q36256469-1E53FD7E-3053-45D2-A135-F5C19FADEBF1 Q36275557-195CE318-668A-4711-8F24-C6287F7F8491 Q36448319-21409D0A-55C5-4F64-9DF3-E855269268FC Q36758314-5101A08C-9678-4683-8BD6-314511A59FCF Q36797503-F51B9730-C93B-4690-A288-7F890B16FBF2 Q36845055-3D6B0786-6DFD-4D61-A8F1-ED81BDFE251C Q36907473-0190C1EF-5292-4667-BE0C-78DE142F8B10 Q36953818-FABE381D-85B5-44E1-9A5A-711B67BD3F64 Q37079289-9229EBFC-DC38-4036-BDED-E79FEA20A3B3 Q37254915-201FC8F1-496C-410F-9177-D6DE77FB06F9 Q37390839-09F26130-017E-4F69-99F5-DBB209330B19 Q37457646-A8B590CA-C412-4731-8EBB-03956859C8B6 Q37568506-93F8329E-B71B-40E1-93E7-836B66ED1BC0 Q37647418-D32ABA80-138B-4151-9F8E-EBABF34C42F2 Q37681515-12C4FAD9-F07F-49A3-A71E-12D260EF9D02 Q37715711-6CC003F7-693B-4F68-9D05-0032F5186620 Q37725539-FA99CD97-489F-45F0-AD1F-BF7CDD152ECF Q38113092-61A6BC4A-ADB3-47C6-A458-12EC7B2D5B27 Q38175855-A6F9E255-AF3F-4972-B90F-04C9C6600A70 Q38182499-619319E0-F1EA-40B1-A9B3-0801654C8632 Q38195527-51934005-5B1B-4065-879A-DC3591EB4455 Q38371242-EA471E17-A8B6-4894-9D76-F78188683766 Q38410742-DF3AE815-8461-4C31-9257-5A3672F5A627 Q38460480-CEC2BCA5-3418-4741-A5E7-473D3E2189AB

P2860

Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.

http://www.wikidata.org/entity/Q44136140

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Dipeptidyl peptidase-4 inhibit ...... ase and uncontrolled diabetes.

@en

Dipeptidyl peptidase-4 inhibit ...... ase and uncontrolled diabetes.

@nl

type

label

Dipeptidyl peptidase-4 inhibit ...... ase and uncontrolled diabetes.

@en

Dipeptidyl peptidase-4 inhibit ...... ase and uncontrolled diabetes.

@nl

prefLabel

Dipeptidyl peptidase-4 inhibit ...... ase and uncontrolled diabetes.

@en

Dipeptidyl peptidase-4 inhibit ...... ase and uncontrolled diabetes.

@nl

P1433

Q44136140-1E76FE33-B667-4B04-90B9-D7E7CC245D32

P1476

Q44136140-4DF2A5AB-53F6-4DF4-92B5-3099E6AFFD64

P2093

Q44136140-1812DB7E-9F2B-4D1D-8320-B0FA0EA82E26

Q44136140-2AEC4BE3-B680-445A-8A2F-AC14C734A592

Q44136140-38EABE65-BFF8-4AF6-A990-4F87153E81A3

Q44136140-43B08550-B13F-4D7B-BAA6-94F2D0F5AA16

Q44136140-4C1BCB19-E08B-4E69-96F6-A59E83444D21

Q44136140-8747CC79-3021-43F4-84E8-93D706F7C83E

Q44136140-A19CE9F6-41C8-452B-905B-4E5729A50A65

Q44136140-B7EE44DC-2B0C-4563-9360-94C26171DCF5

Q44136140-E3954962-9795-4C5D-BE23-16DE337E0580

Q44136140-E95D9AA0-BAF4-4879-AD52-3FAF3699FC9C

P304

Q44136140-87D919FA-15E4-4D8C-B1D3-4FFB27BFDBB5

P31

Q44136140-93D68E76-59EC-4D0D-846C-4C5622454D9E

P356

Q44136140-1AE29DD4-684B-4FB5-9086-CA12DB7D928D

P433

Q44136140-43F51AC3-5F8C-49A9-972C-5186CB48453C

P478

Q44136140-CFA768C3-FCC6-4B12-AC54-ADDE3B932CEC

P577

Q44136140-F57702FA-336A-4DC0-90EA-B32866D1BA31

P698

Q44136140-E176820B-E6EE-4EA5-972D-AE37304F15AD

P921

Q44136140-0A9D3010-44B2-4C1B-BB7B-384A6DD1CB16

Q44136140-DC845690-C312-4ECF-AD41-38DB0BE0E82B

P356

CIRCJ.CJ-12-1168

P1433

Circulation Journal

P1476

Dipeptidyl peptidase-4 inhibit ...... ase and uncontrolled diabetes.

@en

P2093

Eiichi Akiyama

http://www.w3.org/2001/XMLSchema#string

Eiichiro Yamamoto

http://www.w3.org/2001/XMLSchema#string

Hideaki Jinnouchi

http://www.w3.org/2001/XMLSchema#string

Hirofumi Kurokawa

http://www.w3.org/2001/XMLSchema#string

Hirofumi Maeda

http://www.w3.org/2001/XMLSchema#string

Hisao Ogawa

http://www.w3.org/2001/XMLSchema#string

Junichi Matsubara

http://www.w3.org/2001/XMLSchema#string

Keisuke Ohba

http://www.w3.org/2001/XMLSchema#string

Koichi Kaikita

http://www.w3.org/2001/XMLSchema#string

Koichiro Fujisue

http://www.w3.org/2001/XMLSchema#string

P304

1337-1344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1253/CIRCJ.CJ-12-1168

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23386232

http://www.w3.org/2001/XMLSchema#string

P921